Form 4: Phathom Officer Sells Shares for Tax Obligations

Phathom Pharmaceuticals' Principal Accounting Officer, Robert Charles Breedlove, sold 524 shares of common stock to cover tax withholding obligations.

Summary

• Robert Charles Breedlove, the Principal Accounting Officer of Phathom Pharmaceuticals, Inc. (PHAT), reported a transaction on November 3, 2025.
• The transaction involved the sale of 524 shares of Phathom Pharmaceuticals common stock at a price of $13.51 per share.
• The purpose of this sale was to satisfy tax withholding obligations upon the settlement of restricted stock units.
• Following this transaction, Mr. Breedlove directly beneficially owns 47,407 shares of common stock.
• Additionally, Mr. Breedlove indirectly beneficially owns 6,945.4 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale for tax purposes related to equity compensation, which is generally considered a neutral event for investment sentiment.

Positives

• The transaction is a routine compliance action related to equity compensation, indicating the settlement of restricted stock units which are a form of executive compensation.

Negatives

• The sale of shares, while for tax purposes, reduces the direct beneficial ownership of an officer in the company.

Future Outlook

NA

Management Comments

• Shares were sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

Industry Context

This Form 4 filing details a routine insider transaction specific to an individual officer's equity compensation and does not provide broader industry context or trends.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine sale to cover tax obligations related to equity compensation, not a discretionary sale indicating a change in company outlook.

Key Dates

Recommendation

The transaction reported is a non-discretionary sale of shares by an officer to cover tax withholding obligations upon the settlement of restricted stock units. This is a common and routine event for executives receiving equity compensation and does not reflect a discretionary investment decision or a change in the officer's outlook on the company's prospects. Therefore, it does not provide a basis for altering an existing investment recommendation.

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, insider transaction, stock sale, tax withholding, restricted stock units, officer